Vargas Pelaez A, Gao Z, Ahmad T, Leuenberger U, Proctor D, Maman S
Physiol Rep. 2016; 4(10).
PMID: 27225628
PMC: 4886172.
DOI: 10.14814/phy2.12806.
Muller M, Gao Z, Patel H, Heffernan M, Leuenberger U, Sinoway L
Am J Physiol Heart Circ Physiol. 2014; 306(6):H910-7.
PMID: 24441550
PMC: 3949050.
DOI: 10.1152/ajpheart.00787.2013.
Wilkinson R, Stevens I, Pickering M, Robson V, Hawkins T, Kerr D
Br J Clin Pharmacol. 1980; 10(1):51-9.
PMID: 6994760
PMC: 1430025.
DOI: 10.1111/j.1365-2125.1980.tb00501.x.
van der Wall E, Westera G, van Eenige M, Scholtalbers S, Visser F, den Hollander W
Eur J Nucl Med. 1983; 8(10):454-7.
PMID: 6653603
DOI: 10.1007/BF00252946.
Boehringer K, Weidmann P, Link L, Bianchetti M, Schiffl H, REUBI F
Br J Clin Pharmacol. 1983; 15(2):181-8.
PMID: 6133543
PMC: 1427868.
DOI: 10.1111/j.1365-2125.1983.tb01484.x.
Propranolol induces contractions of canine small and large coronary arteries.
Turlapaty P, Altura B
Basic Res Cardiol. 1982; 77(1):68-81.
PMID: 6122440
DOI: 10.1007/BF01908132.
Evidence against beta-adrenoceptor blocking activity of diltiazem, a drug with calcium antagonist properties.
Briley M, Cavero I, Langer S, Roach A
Br J Pharmacol. 1980; 69(4):669-73.
PMID: 6108142
PMC: 2044294.
DOI: 10.1111/j.1476-5381.1980.tb07920.x.
Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.
Heel R, Brogden R, Pakes G, Speight T, Avery G
Drugs. 1980; 20(1):1-23.
PMID: 6105067
DOI: 10.2165/00003495-198020010-00001.
Beta adrenergic receptor activity in peripheral vascular beds of the unanesthetized dog.
Granata L, Braga E, Cevese A, Data P
Pflugers Arch. 1970; 320(1):64-78.
PMID: 5529195
DOI: 10.1007/BF00588457.
[Demonstration of a beta adrenergic dilatation of renal vessels in the awake dog].
Hardt D, Gross R, Kirchheim H
Pflugers Arch. 1971; 327(2):152-66.
PMID: 5105591
DOI: 10.1007/BF00587367.
Deterioration in renal function after beta-blockade in patients with chronic renal failure and hypertension.
Warren D, Swainson C, Wright N
Br Med J. 1974; 2(5912):193-4.
PMID: 4832235
PMC: 1610826.
DOI: 10.1136/bmj.2.5912.193.
Verapamil and the myocardium.
NAYLER W, Krikler D
Postgrad Med J. 1974; 50(585):441-6.
PMID: 4619835
PMC: 2495778.
DOI: 10.1136/pgmj.50.585.441.
Myocardial and haemodynamic effects of the beta-adrenoceptor blocking drug alprenolol (H56/28) in anaesthetized cats.
Parratt J, Wadsworth R
Br J Pharmacol. 1969; 37(2):357-66.
PMID: 4390668
PMC: 1703687.
Influence of carvedilol and propranolol on coronary blood flow.
Sievert H, Frey G, Schrader R, Schmidt T, van der Does R, Kaltenbach M
Eur J Clin Pharmacol. 1990; 38 Suppl 2:S122-4.
PMID: 1974502
DOI: 10.1007/BF01409480.
Verapamil: a review of its pharmacological properties and therapeutic use.
Singh B, Ellrodt G, Peter C
Drugs. 1978; 15(3):169-97.
PMID: 346345
DOI: 10.2165/00003495-197815030-00001.
Coronary and myocardial metabolic effects of combined glyceryl trinitrate and propranolol administration. Observations in patients with and without coronary disease.
Schang Jr S, Pepine C
Br Heart J. 1978; 40(11):1221-8.
PMID: 102330
PMC: 483555.
DOI: 10.1136/hrt.40.11.1221.
beta-Adrenoceptor-blocking agents and the kidney: effect of nadolol and propranolol on the renal circulation.
Hollenberg N, Adams D, MCKINSTRY D, Williams G, Borucki L, Sullivan J
Br J Clin Pharmacol. 1979; 7 Suppl 2:219S-225S.
PMID: 37877
PMC: 1429339.
DOI: 10.1111/j.1365-2125.1979.tb04693.x.
The kidney and antihypertensive therapy.
Bailey R
Drugs. 1976; 11 SUPPL 1:70-7.
PMID: 6253
DOI: 10.2165/00003495-197600111-00019.
